Search

Author/Creator Rippin, Gerd

1. A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses. (7th November 2013)

Authors:
Kallen, Karl-Josef; Gnad-Vogt, Ulrike; Scheel, Birgit; Rippin, Gerd; Stenzl, Arnulf
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 1(2013)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria. (30th April 2020)

Authors:
Yassin, Mohamed A.; Taher, Ali; Mathews, Vikram; Hou, Hsin‐An; Shamsi, Tahir; Tuğlular, Tülin Firatli; Xiao, Zhijian; Kim, Soo‐Jeong; Depei, Wu; Li, Junmin; Rippin, Gerd; Sadek, Islam; Siddiqui, Asif; Wong, Raymond S.
Journal:
Cancer medicine
Issue:
Volume 9:Number 13(2020)
Page Start:
4512
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. Issue 1 (16th June 2015)

Authors:
Kübler, Hubert; Scheel, Birgit; Gnad-Vogt, Ulrike; Miller, Kurt; Schultze-Seemann, Wolfgang; vom Dorp, Frank; Parmiani, Giorgio; Hampel, Christian; Wedel, Steffen; Trojan, Lutz; Jocham, Dieter; Maurer, Tobias; Rippin, Gerd; Fotin-Mleczek, Mariola; von der Mülbe, Florian; Probst, Jochen; Hoerr, In...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3:Issue 1(2015)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗